Skip to main content

Test Price

1,000 AED

✅ Home Collection Available

DRPLA (Dentatorubral-Pallidoluysian Atrophy) Gene Analysis in UAE | 1000 AED | DHA Licensed

Executive Summary & Core Metrics

Accurate Genetic Identification for Informed Care

99.9% diagnostic precision using PCR-based fragment analysis and STR genotyping, performed under ISO 9001‐certified protocols. We offer VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection for blood specimens (available daily 8 AM–11 PM). Results include complementary telephonic consultation with a clinical geneticist. For insurance coverage verification, contact us on WhatsApp at +971 54 548 8731.

Test Overview & Methodology

The DRPLA gene analysis is a definitive molecular test that detects pathogenic CAG trinucleotide repeat expansions in the ATN1 gene, confirming a diagnosis of dentatorubral-pallidoluysian atrophy—a progressive neurodegenerative disorder. This test enables precise clinical classification and family risk assessment.

Feature Our DRPLA Gene Test Closest Alternative (Whole Exome Sequencing)
Methodology PCR‑based Fragment Analysis & STR Genotyping (Capillary Electrophoresis) – gold standard for repeat expansions Short‑read sequencing; often misses repeat‑length variants
Diagnostic Sensitivity 99.9% for ATN1 expanded alleles ~80–90% in repeat regions
Turnaround Time 5 working days (Mon–Fri) 4–6 weeks
Cost 1000 AED Often >5000 AED

Physician Insight & Safety Protocols

“As a Consultant Medical Genetics practicing in the UAE, I have witnessed how a definitive molecular diagnosis for DRPLA can guide families toward tailored management and reproductive planning. This test provides a clear yes-or-no answer regarding the presence of pathological CAG repeats, but it must always be interpreted alongside the patient’s full clinical history and neurological examination. A positive result does not define your future—it opens the door to proactive care.”

— Lina Osama Zaki Quteineh, Consultant Medical Genetics, DHA Registration ID: 9294403

Advisory Precautions

Medication & Clinical Oversight

Do not discontinue any prescribed medications without consulting your physician. This genetic test does not replace ongoing neurological or genetic follow‑up. Always correlate results with your clinical presentation.

Exclusion Criteria & Emergency Red Flags

  • This test is not offered to asymptomatic minors without written parental/legal guardian consent and pre‑test genetic counselling, as required by Federal Law No. 3 of 2016 (Wadeema’s Law).
  • Prenatal diagnosis is performed only after multidisciplinary counselling and informed consent, in accordance with Federal Decree‑Law No. 4 of 2016 on Medical Liability.
  • Results must not be used as the sole basis for major clinical decisions without specialist interpretation.
  • Seek emergency care immediately if you experience: sudden onset of severe involuntary movements, uncontrollable seizures, loss of consciousness, or suicidal ideation after receiving test results.

Patient FAQ & Clinical Guidance

1. What is DRPLA gene analysis and why is it needed?

DRPLA gene analysis detects abnormal CAG repeats in the ATN1 gene, which causes a rare progressive brain disorder characterised by ataxia, chorea, myoclonus, and dementia. The test is recommended for individuals with compatible symptoms and a family history of unexplained neurodegenerative disease. It distinguishes DRPLA from other hereditary ataxias and informs reproductive options through genetic counselling.

2. How should I prepare for the test?

No fasting or special preparation is required. Simply provide a 4 mL peripheral blood sample collected in a lavender‑top EDTA tube. Our VIP Mobile Phlebotomy team will perform the collection at your home between 8 AM and 11 PM and ensure cold‑chain transport. You must also complete the mandatory Genomics Clinical Information Requisition Form (Form 20) with your clinical details.

3. How quickly will I receive my results and what support is available?

Results are delivered within 5 working days. Your report states the exact number of CAG repeats and provides an interpretative summary. Complimentary telephonic guidance from a Consultant Medical Genetics is included to help you understand the implications. If needed, we can arrange a follow‑up with a collaborating neurologist or genetic counsellor.

UAE Regulatory & Data Privacy Adherence

Your Data, Secured & Compliant

DNA Labs UAE operates under DHA Facility License No. 1143. All genetic and personal data are processed in strict compliance with Federal Decree‑Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. Clinical consent and safety protocols follow Federal Decree‑Law No. 4 of 2016 on Medical Liability. Your information is encrypted, anonymised for research only with your explicit consent, and never shared with third parties without legal mandate.

Clinical & Logistical Metadata

Test Name DRPLA (Dentatorubral-Pallidoluysian Atrophy) Gene Analysis (ATN1 CAG Repeat Expansion)
Price (AED) 1,000 AED
Turnaround Time 5 working days
Sample Type / Matrix Peripheral whole blood (4 mL, lavender‑top EDTA tube)
Methodology Used PCR‑based Fragment Analysis & STR Genotyping (Capillary Electrophoresis)
ICD-10-CM Code G11.8 (Other hereditary ataxias, including DRPLA)
LOINC Code 90982-3 (DRPLA gene mutation analysis)
DHA Facility License & Laboratory Address License No. 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE

دعم ثنائي اللغة متاح

التحقق من التغطية التأمينية

Check Insurance Coverage Instantly

Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.

توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.

✅ DHA Certified ✅ ISO 15189 ✅ HIPAA Compliant

Available in Arabic, English, Hindi & Urdu

🏅

ISMS 27001:2022

📋

ISO Accredited

🔒

HIPAA

All reports reviewed by DHA-Certified physicians